Loading...

Marder Stephen

TitleProfessor
InstitutionUniversity of California Los Angeles
DepartmentPsychiatry and Biobehavioral Sciences
AddressBOX 951667 11301 Wilshire Blvd. MIRECC Bldg 210 Rm 130
Los Angeles CA 90073
Phone(800) 825-9989
vCardDownload vCard
    Other Positions
    TitleDirector


    Collapse Research 
    Collapse Research Activities and Funding
    Enhancing Social Cognitive Training with Oxytocin: Linking Target Engagement to Clinical Effects
    NIH/NIMH R33MH107564Aug 15, 2015 - Aug 31, 2020
    Role: Principal Investigator
    Enhancing Social Cognitive Training with Oxytocin: Linking Target Engagement to Clinical Effects
    NIH/NIMH R21MH107564Aug 15, 2015 - May 31, 2017
    Role: Principal Investigator
    Opportunities for Innovative Drug Development for Schizophrenia
    NIH/NIMH R13MH085413Aug 12, 2009 - Jul 31, 2011
    Role: Principal Investigator
    Relapse Prevention: Long-Acting Atypical Antipsychotics
    NIH/NIMH U01MH070012Feb 1, 2006 - Dec 31, 2011
    Role: Co-Principal Investigator
    TREATMENT UNITS FOR RESEARCH ON NEUROCOGNITION &SCHIZOPHRENIA (TURNS)
    NIH/NIMH N01MH41003May 3, 2004 - Jul 31, 2009
    Role: Co-Principal Investigator
    TREATMENT OF NEGATIVE SYMPTOMS &COGNITIVE IMPAIRMENTS
    NIH/NIMH R01MH059750Jan 15, 2000 - Jul 31, 2005
    Role: Principal Investigator
    NEW ANTIPSYCHOTICS--CLINICAL TRIALS AND FOLLOWUP
    NIH/NIMH R01MH046484Mar 1, 1992 - Feb 28, 1999
    Role: Principal Investigator
    MANAGEMENT FOR RISK OF RELAPSE IN SCHIZOPHRENIA
    NIH/NIMH R01MH041573Jul 1, 1986 - Jan 31, 2007
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Breier A, Buchanan RW, D'Souza D, Nuechterlein K, Marder S, Dunn W, Preskorn S, Macaluso M, Wurfel B, Maguire G, Kakar R, Highum D, Hoffmeyer D, Coskinas E, Litman R, Vohs JL, Radnovich A, Francis MM, Metzler E, Visco A, Mehdiyoun N, Yang Z, Zhang Y, Yolken RH, Dickerson FB. Herpes simplex virus 1 infection and valacyclovir treatment in schizophrenia: Results from the VISTA study. Schizophr Res. 2018 Nov 23. PMID: 30478008.
      View in: PubMed
    2. Marder S, Fleischhacker WW, Earley W, Lu K, Zhong Y, Németh G, Laszlovszky I, Szalai E, Durgam S. Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies. Eur Neuropsychopharmacol. 2018 Nov 20. PMID: 30470662.
      View in: PubMed
    3. Wynn JK, Green MF, Hellemann G, Reavis EA, Marder SR. A dose-finding study of oxytocin using neurophysiological measures of social processing. Neuropsychopharmacology. 2018 Jul 28. PMID: 30082892.
      View in: PubMed
    4. Marder SR, Zito MF. "Will I need to take these medications for the rest of my life?" World Psychiatry. 2018 Jun; 17(2):165-166. PMID: 29856554.
      View in: PubMed
    5. Faerden A, Lyngstad SH, Simonsen C, Ringen PA, Papsuev O, Dieset I, Andreassen OA, Agartz I, Marder SR, Melle I. Reliability and validity of the self-report version of the apathy evaluation scale in first-episode Psychosis: Concordance with the clinical version at baseline and 12 months follow-up. Psychiatry Res. 2018 May 31; 267:140-147. PMID: 29906681.
      View in: PubMed
    6. Anderson AE, Marder S, Reise SP, Savitz A, Salvadore G, Fu DJ, Li Q, Turkoz I, Han C, Bilder RM. Bifactor Modeling of the Positive and Negative Syndrome Scale: Generalized Psychosis Spans Schizoaffective, Bipolar, and Schizophrenia Diagnoses. Schizophr Bull. 2018 Feb 06. PMID: 29420822.
      View in: PubMed
    7. Marder SR, Laughren T, Romano SJ. The Importance of Adequately Powered Clinical Studies: Response to Khan et al. Am J Psychiatry. 2018 Feb 01; 175(2):188-189. PMID: 29385831.
      View in: PubMed
    8. Anderson AE, Reise SP, Marder SR, Mansolf M, Han C, Bilder RM. Disparity between General Symptom Relief and Remission Criteria in the Positive and Negative Syndrome Scale (PANSS): A Post-treatment Bifactor Item Response Theory Model. Innov Clin Neurosci. 2017 Dec 01; 14(11-12):41-53. PMID: 29410936.
      View in: PubMed
    9. Reddy LF, Horan WP, Barch DM, Buchanan RW, Gold JM, Marder SR, Wynn JK, Young J, Green MF. Understanding the Association Between Negative Symptoms and Performance on Effort-Based Decision-Making Tasks: The Importance of Defeatist Performance Beliefs. Schizophr Bull. 2017 Nov 13. PMID: 29140501.
      View in: PubMed
    10. Wynn JK, Green MF, Hellemann G, Karunaratne K, Davis MC, Marder SR. The effects of curcumin on brain-derived neurotrophic factor and cognition in schizophrenia: A randomized controlled study. Schizophr Res. 2018 May; 195:572-573. PMID: 28965778.
      View in: PubMed
    11. Hurford IM, Ventura J, Marder SR, Reise SP, Bilder RM. A 10-minute measure of global cognition: Validation of the Brief Cognitive Assessment Tool for Schizophrenia (B-CATS). Schizophr Res. 2018 May; 195:327-333. PMID: 28918221.
      View in: PubMed
    12. Noordsy DL, Glynn SM, Sugar CA, O'Keefe CD, Marder SR. Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes. J Psychiatr Res. 2017 Dec; 95:299-307. PMID: 28942217.
      View in: PubMed
    13. Marder SR, Laughren T, Romano SJ. Why Are Innovative Drugs Failing in Phase III? Am J Psychiatry. 2017 Sep 01; 174(9):829-831. PMID: 28859511.
      View in: PubMed
    14. Keefe RSE, Davis VG, Harvey PD, Atkins AS, Haig GM, Hagino O, Marder S, Hilt DC, Umbricht D. Placebo Response and Practice Effects in Schizophrenia Cognition Trials. JAMA Psychiatry. 2017 Aug 01; 74(8):807-814. PMID: 28636694.
      View in: PubMed
    15. Chappell PB, Stewart M, Alphs L, DiCesare F, DuBrava S, Harkavy-Friedman J, Lim P, Ratcliffe S, Silverman MM, Targum SD, Marder SR. Assessment of Suicidal Ideation and Behavior: Report of the International Society for CNS Clinical Trials and Methodology Consensus Meeting. J Clin Psychiatry. 2017 Jun; 78(6):e638-e647. PMID: 28682533.
      View in: PubMed
    16. Marder SR, Gitlin MJ. A Cruel Irony for Clinicians Who Treat Depression. Am J Psychiatry. 2017 05 01; 174(5):409-410. PMID: 28457149.
      View in: PubMed
    17. Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, Burke J, Liang GS, O'Brien CF. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. Am J Psychiatry. 2017 05 01; 174(5):476-484. PMID: 28320223.
      View in: PubMed
    18. Németh G, Laszlovszky I, Czobor P, Szalai E, Szatmári B, Harsányi J, Barabássy Á, Debelle M, Durgam S, Bitter I, Marder S, Fleischhacker WW. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017 03 18; 389(10074):1103-1113. PMID: 28185672.
      View in: PubMed
    19. Marder SR, Galderisi S. The current conceptualization of negative symptoms in schizophrenia. World Psychiatry. 2017 Feb; 16(1):14-24. PMID: 28127915.
      View in: PubMed
    20. Buck B, Iwanski C, Healey KM, Green MF, Horan WP, Kern RS, Lee J, Marder SR, Reise SP, Penn DL. Improving measurement of attributional style in schizophrenia; A psychometric evaluation of the Ambiguous Intentions Hostility Questionnaire (AIHQ). J Psychiatr Res. 2017 Jun; 89:48-54. PMID: 28160626.
      View in: PubMed
    21. Bugarski-Kirola D, Blaettler T, Arango C, Fleischhacker WW, Garibaldi G, Wang A, Dixon M, Bressan RA, Nasrallah H, Lawrie S, Napieralski J, Ochi-Lohmann T, Reid C, Marder SR. Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies. Biol Psychiatry. 2017 07 01; 82(1):8-16. PMID: 28117049.
      View in: PubMed
    22. Marder SR, Hakala MJ, Josiassen MK, Zhang P, Ouyang J, Weiller E, Weiss C, Hobart M. Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies. Acta Neuropsychiatr. 2017 Oct; 29(5):278-290. PMID: 27846922.
      View in: PubMed
    23. Cohen AN, Hamilton AB, Saks ER, Glover DL, Glynn SM, Brekke JS, Marder SR. How Occupationally High-Achieving Individuals With a Diagnosis of Schizophrenia Manage Their Symptoms. Psychiatr Serv. 2017 Apr 01; 68(4):324-329. PMID: 27842472.
      View in: PubMed
    24. Glynn SM, Marder SR, Noordsy DL, O'Keefe C, Becker DR, Drake RE, Sugar CA. An RCT Evaluating the Effects of Skills Training and Medication Type on Work Outcomes Among Patients With Schizophrenia. Psychiatr Serv. 2017 Mar 01; 68(3):271-277. PMID: 27799019.
      View in: PubMed
    25. Dunayevich E, Buchanan RW, Chen CY, Yang J, Nilsen J, Dietrich JM, Sun H, Marder S. Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia. Schizophr Res. 2017 04; 182:90-97. PMID: 27789188.
      View in: PubMed
    26. Sultzer DL, Marder SR. Older Brains are Different: Brain-Behavior Studies and Their Clinical Utility. Am J Geriatr Psychiatry. 2017 Jan; 25(1):11-12. PMID: 28231870.
      View in: PubMed
    27. Krystal JH, Abi-Dargham A, Akbarian S, Arnsten AFT, Barch DM, Bearden CE, Braff DL, Brown ES, Bullmore ET, Carlezon WA, Carter CS, Cook EH, Daskalakis ZJ, DiLeone RJ, Duman RS, Grace AA, Hariri AR, Harrison PJ, Hiroi N, Kenny PJ, Kleinman JE, Krystal AD, Lewis DA, Lipska BK, Marder SR, Mason GF, Mathalon DH, McClung CA, McDougle CJ, McIntosh AM, McMahon FJ, Mirnics K, Monteggia LM, Narendran R, Nestler EJ, Neumeister A, O'Donovan MC, Öngür D, Pariante CM, Paulus MP, Pearlson G, Phillips ML, Pine DS, Pizzagalli DA, Pletnikov MV, Ragland JD, Rapoport JL, Ressler KJ, Russo SJ, Sanacora G, Sawa A, Schatzberg AF, Shaham Y, Shamay-Tsoory SG, Sklar P, State MW, Stein MB, Strakowski SM, Taylor SF, Turecki G, Turetsky BI, Weissman MM, Zachariou V, Zarate CA, Zubieta JK. Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research. Biol Psychiatry. 2016 07 15; 80(2):84-86. PMID: 27346079.
      View in: PubMed
    28. Barch DM, Marder SR, Harms MP, Jarskog LF, Buchanan RW, Cronenwett W, Chen LS, Weiss M, Maguire RP, Pezous N, Feuerbach D, Lopez-Lopez C, Johns DR, Behrje RB, Gomez-Mancilla B. Task-related fMRI responses to a nicotinic acetylcholine receptor partial agonist in schizophrenia: A randomized trial. Prog Neuropsychopharmacol Biol Psychiatry. 2016 11 03; 71:66-75. PMID: 27371157.
      View in: PubMed
    29. Schooler NR, Marder SR, Chengappa KN, Petrides G, Ames D, Wirshing WC, McMeniman M, Baker RW, Parepally H, Umbricht D, Kane JM. Clozapine and risperidone in moderately refractory schizophrenia: a 6-month randomized double-blind comparison. J Clin Psychiatry. 2016 May; 77(5):628-34. PMID: 27035871.
      View in: PubMed
    30. Marder SR. Alpha-7 nicotinic agonist improves cognition in schizophrenia. Evid Based Ment Health. 2016 05; 19(2):60. PMID: 26872633.
      View in: PubMed
    31. Marder SR. Community Evidence of Clozapine's Effectiveness. Am J Psychiatry. 2016 Feb 01; 173(2):103-4. PMID: 26844790.
      View in: PubMed
    32. Keefe RS, Haig GM, Marder SR, Harvey PD, Dunayevich E, Medalia A, Davidson M, Lombardo I, Bowie CR, Buchanan RW, Bugarski-Kirola D, Carpenter WT, Csernansky JT, Dago PL, Durand DM, Frese FJ, Goff DC, Gold JM, Hooker CI, Kopelowicz A, Loebel A, McGurk SR, Opler LA, Pinkham AE, Stern RG. Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia. Schizophr Bull. 2016 Jan; 42(1):19-33. PMID: 26362273.
      View in: PubMed
    33. Mohamed S, Johnson GR, Vertrees JE, Guarino PD, Weingart K, Young IT, Yoon J, Gleason TC, Kirkwood KA, Kilbourne AM, Gerrity M, Marder S, Biswas K, Hicks P, Davis LL, Chen P, Kelada A, Huang GD, Lawrence DD, LeGwin M, Zisook S. The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations. Psychiatry Res. 2015 Oct 30; 229(3):760-70. PMID: 26279130.
      View in: PubMed
    34. Subotnik KL, Casaus LR, Ventura J, Luo JS, Hellemann GS, Gretchen-Doorly D, Marder S, Nuechterlein KH. Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial. JAMA Psychiatry. 2015 Aug; 72(8):822-9. PMID: 26107752.
      View in: PubMed
    35. Reddy LF, Horan WP, Barch DM, Buchanan RW, Dunayevich E, Gold JM, Lyons N, Marder SR, Treadway MT, Wynn JK, Young JW, Green MF. Effort-Based Decision-Making Paradigms for Clinical Trials in Schizophrenia: Part 1—Psychometric Characteristics of 5 Paradigms. Schizophr Bull. 2015 Sep; 41(5):1045-54. PMID: 26142081; PMCID: PMC4535649.
    36. Walling D, Marder SR, Kane J, Fleischhacker WW, Keefe RS, Hosford DA, Dvergsten C, Segreti AC, Beaver JS, Toler SM, Jett JE, Dunbar GC. Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia. Schizophr Bull. 2016 Mar; 42(2):335-43. PMID: 26071208; PMCID: PMC4753586 [Available on 03/01/17].
    37. Jarskog LF, Lowy MT, Grove RA, Keefe RS, Horrigan JP, Ball MP, Breier A, Buchanan RW, Carter CS, Csernansky JG, Goff DC, Green MF, Kantrowitz JT, Keshavan MS, Laurelle M, Lieberman JA, Marder SR, Maruff P, McMahon RP, Seidman LJ, Peykamian MA. A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. Schizophr Res. 2015 May; 164(1-3):136-42. PMID: 25728831.
      View in: PubMed
    38. Nemeroff CB, Marder SR, Lieberman J. Ellen Stover. Neuropsychopharmacology. 2014 Dec; 39(13):3132. PMID: 25381709; PMCID: PMC4229591.
    39. Dunayevich E, Chen CY, Marder SR, Rabinowitz J. Restrictive symptomatic inclusion criteria create barriers to clinical research in schizophrenia negative symptoms: an analysis of the CATIE dataset. Eur Neuropsychopharmacol. 2014 Oct; 24(10):1615-21. PMID: 25172269.
      View in: PubMed
    40. Marder SR, Freedman R. Learning from people with schizophrenia. Schizophr Bull. 2014 Nov; 40(6):1185-6. PMID: 24973131; PMCID: PMC4193727.
    41. Edgar CJ, Blaettler T, Bugarski-Kirola D, Le Scouiller S, Garibaldi GM, Marder SR. Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms. Psychiatry Res. 2014 Aug 15; 218(1-2):219-24. PMID: 24809242.
      View in: PubMed
    42. Marder SR. Perspective: Retreat from the radical. Nature. 2014 Apr 03; 508(7494):S18. PMID: 24695331.
      View in: PubMed
    43. Fleischhacker WW, Arango C, Arteel P, Barnes TR, Carpenter W, Duckworth K, Galderisi S, Halpern L, Knapp M, Marder SR, Moller M, Sartorius N, Woodruff P. Schizophrenia--time to commit to policy change. Schizophr Bull. 2014 Apr; 40 Suppl 3:S165-94. PMID: 24778411; PMCID: PMC4002061.
    44. Davis MC, Green MF, Lee J, Horan WP, Senturk D, Clarke AD, Marder SR. Oxytocin-augmented social cognitive skills training in schizophrenia. Neuropsychopharmacology. 2014 Aug; 39(9):2070-7. PMID: 24637803; PMCID: PMC4104336.
    45. Marder SR, Kirkpatrick B. Defining and measuring negative symptoms of schizophrenia in clinical trials. Eur Neuropsychopharmacol. 2014 May; 24(5):737-43. PMID: 24275698.
      View in: PubMed
    46. Velligan DI, Fredrick M, Mintz J, Li X, Rubin M, Dube S, Deshpande SN, Trivedi JK, Gautam S, Avasthi A, Kern RS, Marder SR. The reliability and validity of the MATRICS functional assessment battery. Schizophr Bull. 2014 Sep; 40(5):1047-52. PMID: 24214931; PMCID: PMC4133666.
    47. Davis MC, Horan WP, Marder SR. Psychopharmacology of the negative symptoms: current status and prospects for progress. Eur Neuropsychopharmacol. 2014 May; 24(5):788-99. PMID: 24252823.
      View in: PubMed
    48. Marder SR, Rabinowitz J, Kapur S. Clinical trials for negative symptoms--emerging directions and unresolved issues. Schizophr Res. 2013 Nov; 150(2-3):327. PMID: 24209763.
      View in: PubMed
    49. Marder SR. Monitoring treatment and managing adherence in schizophrenia. J Clin Psychiatry. 2013 Oct; 74(10):e21. PMID: 24229761.
      View in: PubMed
    50. Olbert CM, Penn DL, Kern RS, Lee J, Horan WP, Reise SP, Ochsner KN, Marder SR, Green MF. Adapting social neuroscience measures for schizophrenia clinical trials, part 3: fathoming external validity. Schizophr Bull. 2013 Nov; 39(6):1211-8. PMID: 24072806; PMCID: PMC3796091.
    51. Kern RS, Penn DL, Lee J, Horan WP, Reise SP, Ochsner KN, Marder SR, Green MF. Adapting social neuroscience measures for schizophrenia clinical trials, Part 2: trolling the depths of psychometric properties. Schizophr Bull. 2013 Nov; 39(6):1201-10. PMID: 24072805; PMCID: PMC3796089.
    52. Marder SR, Alphs L, Anghelescu IG, Arango C, Barnes TR, Caers I, Daniel DG, Dunayevich E, Fleischhacker WW, Garibaldi G, Green MF, Harvey PD, Kahn RS, Kane JM, Keefe RS, Kinon B, Leucht S, Lindenmayer JP, Malhotra AK, Stauffer V, Umbricht D, Wesnes K, Kapur S, Rabinowitz J. Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophr Res. 2013 Nov; 150(2-3):328-33. PMID: 24028744.
      View in: PubMed
    53. Arango C, Garibaldi G, Marder SR. Pharmacological approaches to treating negative symptoms: a review of clinical trials. Schizophr Res. 2013 Nov; 150(2-3):346-52. PMID: 23938176.
      View in: PubMed
    54. Rabinowitz J, Berardo CG, Bugarski-Kirola D, Marder S. Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis. Schizophr Res. 2013 Nov; 150(2-3):339-42. PMID: 23899997.
      View in: PubMed
    55. Davis MC, Lee J, Horan WP, Clarke AD, McGee MR, Green MF, Marder SR. Effects of single dose intranasal oxytocin on social cognition in schizophrenia. Schizophr Res. 2013 Jul; 147(2-3):393-7. PMID: 23676253.
      View in: PubMed
    56. Pato MT, Sobell JL, Medeiros H, Abbott C, Sklar BM, Buckley PF, Bromet EJ, Escamilla MA, Fanous AH, Lehrer DS, Macciardi F, Malaspina D, McCarroll SA, Marder SR, Moran J, Morley CP, Nicolini H, Perkins DO, Purcell SM, Rapaport MH, Sklar P, Smoller JW, Knowles JA. The genomic psychiatry cohort: partners in discovery. Am J Med Genet B Neuropsychiatr Genet. 2013 Jun; 162B(4):306-12. PMID: 23650244.
      View in: PubMed
    57. Faerden A, Barrett EA, Nesvåg R, Friis S, Finset A, Marder SR, Ventura J, Andreassen OA, Agartz I, Melle I. Apathy, poor verbal memory and male gender predict lower psychosocial functioning one year after the first treatment of psychosis. Psychiatry Res. 2013 Nov 30; 210(1):55-61. PMID: 23489592; PMCID: PMC4066735.
    58. Jarskog LF, Dong Z, Kangarlu A, Colibazzi T, Girgis RR, Kegeles LS, Barch DM, Buchanan RW, Csernansky JG, Goff DC, Harms MP, Javitt DC, Keefe RS, McEvoy JP, McMahon RP, Marder SR, Peterson BS, Lieberman JA. Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology. 2013 Jun; 38(7):1245-52. PMID: 23325325.
      View in: PubMed
    59. Marder SR. Clinician perceptions, expectations, and management of negative symptoms in schizophrenia. J Clin Psychiatry. 2013 Jan; 74(1):e01. PMID: 23419229.
      View in: PubMed
    60. Sherer EA, Sale ME, Pollock BG, Belani CP, Egorin MJ, Ivy PS, Lieberman JA, Manuck SB, Marder SR, Muldoon MF, Scher HI, Solit DB, Bies RR. Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building. J Pharmacokinet Pharmacodyn. 2012 Aug; 39(4):393-414. PMID: 22767341; PMCID: PMC3400037.
    61. Marder SR. Clinical instruments to evaluate and guide treatment in schizophrenia. Handb Exp Pharmacol. 2012; (213):1-10. PMID: 23027410.
      View in: PubMed
    62. Javitt DC, Buchanan RW, Keefe RS, Kern R, McMahon RP, Green MF, Lieberman J, Goff DC, Csernansky JG, McEvoy JP, Jarskog F, Seidman LJ, Gold JM, Kimhy D, Nolan KS, Barch DS, Ball MP, Robinson J, Marder SR. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res. 2012 Apr; 136(1-3):25-31. PMID: 22169248.
      View in: PubMed
    63. Glick ID, Correll CU, Altamura AC, Marder SR, Csernansky JG, Weiden PJ, Leucht S, Davis JM. Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach. J Clin Psychiatry. 2011 Dec; 72(12):1616-27. PMID: 22244023.
      View in: PubMed
    64. Keefe RS, Buchanan RW, Marder SR, Schooler NR, Dugar A, Zivkov M, Stewart M. Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? Schizophr Bull. 2013 Mar; 39(2):417-35. PMID: 22114098.
      View in: PubMed
    65. Marder SR, Roth B, Sullivan PF, Scolnick EM, Nestler EJ, Geyer MA, Welnberger DR, Karayiorgou M, Guidotti A, Gingrich J, Akbarian S, Buchanan RW, Lieberman JA, Conn PJ, Haggarty SJ, Law AJ, Campbell B, Krystal JH, Moghaddam B, Sawa A, Saw A, Caron MG, George SR, Allen JA, Solis M. Advancing drug discovery for schizophrenia. Ann N Y Acad Sci. 2011 Oct; 1236:30-43. PMID: 22032400; PMCID: PMC3787879.
    66. Horan WP, Kern RS, Tripp C, Hellemann G, Wynn JK, Bell M, Marder SR, Green MF. Efficacy and specificity of social cognitive skills training for outpatients with psychotic disorders. J Psychiatr Res. 2011 Aug; 45(8):1113-22. PMID: 21377168; PMCID: PMC4064828.
    67. Marder SR. Lessons from MATRICS. Schizophr Bull. 2011 Mar; 37(2):233-4. PMID: 21325472; PMCID: PMC3044624.
    68. Green MF, Schooler NR, Kern RS, Frese FJ, Granberry W, Harvey PD, Karson CN, Peters N, Stewart M, Seidman LJ, Sonnenberg J, Stone WS, Walling D, Stover E, Marder SR. Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. Am J Psychiatry. 2011 Apr; 168(4):400-7. PMID: 21285142.
      View in: PubMed
    69. Marder SR, Daniel DG, Alphs L, Awad AG, Keefe RS. Methodological issues in negative symptom trials. Schizophr Bull. 2011 Mar; 37(2):250-4. PMID: 21270473; PMCID: PMC3044631.
    70. Wessels AM, Bies RR, Pollock BG, Schneider LS, Lieberman JA, Stroup S, Li CH, Coley K, Kirshner MM, Marder SR. Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study. J Clin Pharmacol. 2011 Nov; 51(11):1587-91. PMID: 21209243.
      View in: PubMed
    71. Subotnik KL, Nuechterlein KH, Ventura J, Gitlin MJ, Marder S, Mintz J, Hellemann GS, Thornton LA, Singh IR. Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am J Psychiatry. 2011 Mar; 168(3):286-92. PMID: 21205805.
      View in: PubMed
    72. Kern RS, Gold JM, Dickinson D, Green MF, Nuechterlein KH, Baade LE, Keefe RS, Mesholam-Gately RI, Seidman LJ, Lee C, Sugar CA, Marder SR. The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. Schizophr Res. 2011 Mar; 126(1-3):124-31. PMID: 21159492; PMCID: PMC3050090.
    73. Buchanan RW, Keefe RS, Lieberman JA, Barch DM, Csernansky JG, Goff DC, Gold JM, Green MF, Jarskog LF, Javitt DC, Kimhy D, Kraus MS, McEvoy JP, Mesholam-Gately RI, Seidman LJ, Ball MP, McMahon RP, Kern RS, Robinson J, Marder SR. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry. 2011 Mar 01; 69(5):442-9. PMID: 21145041; PMCID: PMC3058394.
    74. Velligan DI, Rubin M, Fredrick MM, Mintz J, Nuechterlein KH, Schooler NR, Jaeger J, Peters NM, Buller R, Marder SR, Dube S. The cultural adaptability of intermediate measures of functional outcome in schizophrenia. Schizophr Bull. 2012 May; 38(3):630-41. PMID: 21134973; PMCID: PMC3329974.
    75. Wessels AM, Pollock BG, Anyama NG, Schneider LS, Lieberman JA, Marder SR, Bies RR. Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial. J Clin Psychopharmacol. 2010 Dec; 30(6):683-7. PMID: 21105282.
      View in: PubMed
    76. Young AS, Niv N, Chinman M, Dixon L, Eisen SV, Fischer EP, Smith J, Valenstein M, Marder SR, Owen RR. Routine outcomes monitoring to support improving care for schizophrenia: report from the VA Mental Health QUERI. Community Ment Health J. 2011 Apr; 47(2):123-35. PMID: 20658320; PMCID: PMC3058510.
    77. Kirkpatrick B, Strauss GP, Nguyen L, Fischer BA, Daniel DG, Cienfuegos A, Marder SR. The brief negative symptom scale: psychometric properties. Schizophr Bull. 2011 Mar; 37(2):300-5. PMID: 20558531; PMCID: PMC3044634.
    78. Buchanan RW, Keefe RS, Umbricht D, Green MF, Laughren T, Marder SR. The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophr Bull. 2011 Nov; 37(6):1209-17. PMID: 20410237; PMCID: PMC3196938.
    79. Keefe RS, Vinogradov S, Medalia A, Silverstein SM, Bell MD, Dickinson D, Ventura J, Marder SR, Stroup TS. Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia. Schizophr Bull. 2011 Sep; 37(5):1057-65. PMID: 20194249; PMCID: PMC3160227.
    80. Marder SR, Sorsaburu S, Dunayevich E, Karagianis JL, Dawe IC, Falk DM, Dellva MA, Carlson JL, Cavazzoni PA, Baker RW. Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation. J Clin Psychiatry. 2010 Apr; 71(4):433-41. PMID: 20156413.
      View in: PubMed
    81. Faerden A, Finset A, Friis S, Agartz I, Barrett EA, Nesvåg R, Andreassen OA, Marder SR, Melle I. Apathy in first episode psychosis patients: one year follow up. Schizophr Res. 2010 Jan; 116(1):20-6. PMID: 19948392.
      View in: PubMed
    82. Jin Y, Pollock BG, Coley K, Miller D, Marder SR, Florian J, Schneider L, Lieberman J, Kirshner M, Bies RR. Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking. J Clin Pharmacol. 2010 Jan; 50(1):73-80. PMID: 19843655; PMCID: PMC3648660.
    83. Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester-Blokland E, Sun W, Carson WH, Pikalov A, Assunção-Talbott S. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry. 2009 Oct; 70(10):1348-57. PMID: 19906340.
      View in: PubMed
    84. Hurford IM, Marder SR, Keefe RS, Reise SP, Bilder RM. A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians. Schizophr Bull. 2011 May; 37(3):538-45. PMID: 19776205; PMCID: PMC3080688.
    85. Kern RS, Glynn SM, Horan WP, Marder SR. Psychosocial treatments to promote functional recovery in schizophrenia. Schizophr Bull. 2009 Mar; 35(2):347-61. PMID: 19176470; PMCID: PMC2659313.
    86. Janicak PG, Glick ID, Marder SR, Crandall DT, McQuade RD, Marcus RN, Eudicone JM, Assunção-Talbott S. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. J Clin Psychiatry. 2009 Jan; 70(1):25-35. PMID: 19192472.
      View in: PubMed
    87. Webber MA, Marder SR. Better pharmacotherapy for schizophrenia: what does the future hold? Curr Psychiatry Rep. 2008 Aug; 10(4):352-8. PMID: 18627675.
      View in: PubMed
    88. Feng Y, Pollock BG, Coley K, Marder S, Miller D, Kirshner M, Aravagiri M, Schneider L, Bies RR. Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br J Clin Pharmacol. 2008 Nov; 66(5):629-39. PMID: 18771484; PMCID: PMC2661978.
    89. Faerden A, Nesvåg R, Marder SR. Definitions of the term 'recovered' in schizophrenia and other disorders. Psychopathology. 2008; 41(5):271-8. PMID: 18594161.
      View in: PubMed
    90. Marder SR. Treatment of agitation in patients with schizophrenia. J Clin Psychiatry. 2008 Jun; 69(6):e17. PMID: 18683992.
      View in: PubMed
    91. Krystal JH, Carter CS, Geschwind D, Manji HK, March JS, Nestler EJ, Zubieta JK, Charney DS, Goldman D, Gur RE, Lieberman JA, Roy-Byrne P, Rubinow DR, Anderson SA, Barondes S, Berman KF, Blair J, Braff DL, Brown ES, Calabrese JR, Carlezon WA, Cook EH, Davidson RJ, Davis M, Desimone R, Drevets WC, Duman RS, Essock SM, Faraone SV, Freedman R, Friston KJ, Gelernter J, Geller B, Gill M, Gould E, Grace AA, Grillon C, Gueorguieva R, Hariri AR, Innis RB, Jones EG, Kleinman JE, Koob GF, Krystal AD, Leibenluft E, Levinson DF, Levitt PR, Lewis DA, Liberzon I, Lipska BK, Marder SR, Markou A, Mason GF, McDougle CJ, McEwen BS, McMahon FJ, Meaney MJ, Meltzer HY, Merikangas KR, Meyer-Lindenberg A, Mirnics K, Monteggia LM, Neumeister A, O'Brien CP, Owen MJ, Pine DS, Rapoport JL, Rauch SL, Robbins TW, Rosenbaum JF, Rosenberg DR, Ross CA, Rush AJ, Sackeim HA, Sanacora G, Schatzberg AF, Shaham Y, Siever LJ, Sunderland T, Tecott LH, Thase ME, Todd RD, Weissman MM, Yehuda R, Yoshikawa T, Young EA, McCandless R. It is time to take a stand for medical research and against terrorism targeting medical scientists. Biol Psychiatry. 2008 Apr 15; 63(8):725-7. PMID: 18371494.
      View in: PubMed
    92. Zhu B, Ascher-Svanum H, Shi L, Faries D, Montgomery W, Marder SR. Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia. Psychiatr Serv. 2008 Mar; 59(3):315-7. PMID: 18308914.
      View in: PubMed
    93. Bigos KL, Pollock BG, Coley KC, Miller DD, Marder SR, Aravagiri M, Kirshner MA, Schneider LS, Bies RR. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol. 2008 Feb; 48(2):157-65. PMID: 18199892.
      View in: PubMed
    94. Kim JH, Kim D, Marder SR. Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008 May 15; 32(4):984-8. PMID: 18262321.
      View in: PubMed
    95. Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, Keefe RS, Mesholam-Gately R, Mintz J, Seidman LJ, Stover E, Marder SR. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry. 2008 Feb; 165(2):214-20. PMID: 18172018.
      View in: PubMed
    96. Green MF, Nuechterlein KH, Kern RS, Baade LE, Fenton WS, Gold JM, Keefe RS, Mesholam-Gately R, Seidman LJ, Stover E, Marder SR. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. Am J Psychiatry. 2008 Feb; 165(2):221-8. PMID: 18172017.
      View in: PubMed
    97. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008 Feb; 165(2):203-13. PMID: 18172019.
      View in: PubMed
    98. Foerde K, Poldrack RA, Khan BJ, Sabb FW, Bookheimer SY, Bilder RM, Guthrie D, Granholm E, Nuechterlein KH, Marder SR, Asarnow RF. Selective corticostriatal dysfunction in schizophrenia: examination of motor and cognitive skill learning. Neuropsychology. 2008 Jan; 22(1):100-9. PMID: 18211159.
      View in: PubMed
    99. Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Essock SM, Finnerty M, Marder SR, Miller DD, McEvoy JP, Robinson DG, Schooler NR, Shon SP, Stroup TS, Miller AL. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry. 2007 Nov; 68(11):1751-62. PMID: 18052569.
      View in: PubMed
    100. Marder SR. Newer antipsychotics and the differences between clinical experiences and clinical trials. Interview by Norman Sussman, MD. CNS Spectr. 2007 Nov; 12(11):812-5. PMID: 18084854.
      View in: PubMed
    101. Bratti IM, Kane JM, Marder SR. Chronic restlessness with antipsychotics. Am J Psychiatry. 2007 Nov; 164(11):1648-54. PMID: 17974927.
      View in: PubMed
    102. Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry. 2007 Oct; 164(10):1593-602. PMID: 17898352.
      View in: PubMed
    103. Sergi MJ, Green MF, Widmark C, Reist C, Erhart S, Braff DL, Kee KS, Marder SR, Mintz J. Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. Am J Psychiatry. 2007 Oct; 164(10):1585-92. PMID: 17898351.
      View in: PubMed
    104. Stover EL, Brady L, Marder SR. New paradigms for treatment development. Schizophr Bull. 2007 Sep; 33(5):1093-9. PMID: 17673495; PMCID: PMC2632353.
    105. Wynn JK, Green MF, Sprock J, Light GA, Widmark C, Reist C, Erhart S, Marder SR, Mintz J, Braff DL. Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. Schizophr Res. 2007 Sep; 95(1-3):134-42. PMID: 17662577; PMCID: PMC2716219.
    106. Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, Lowy A. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry. 2007 Dec 15; 62(12):1363-70. PMID: 17601495.
      View in: PubMed
    107. Pierre JM, Peloian JH, Wirshing DA, Wirshing WC, Marder SR. A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. J Clin Psychiatry. 2007 May; 68(5):705-10. PMID: 17503979.
      View in: PubMed
    108. Marder SR, West B, Lau GS, Pultz JA, Pikalov A, Marcus RN, Gutierrez-Esteinou R, Crandall DT. Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials. J Clin Psychiatry. 2007 May; 68(5):662-8. PMID: 17503974.
      View in: PubMed
    109. Shi L, Ascher-Svanum H, Zhu B, Faries D, Montgomery W, Marder SR. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv. 2007 Apr; 58(4):482-8. PMID: 17412849.
      View in: PubMed
    110. Marder SR. Lessons from each drug trial. Am J Psychiatry. 2007 Mar; 164(3):375-6. PMID: 17329457.
      View in: PubMed
    111. Davis JM, Marder SR, Tamminga CA. Switch or stay? Am J Psychiatry. 2006 Dec; 163(12):2032-3. PMID: 17151147.
      View in: PubMed
    112. Sergi MJ, Rassovsky Y, Widmark C, Reist C, Erhart S, Braff DL, Marder SR, Green MF. Social cognition in schizophrenia: relationships with neurocognition and negative symptoms. Schizophr Res. 2007 Feb; 90(1-3):316-24. PMID: 17141477.
      View in: PubMed
    113. Aravagiri M, Marder SR, Pollock B. Determination of ziprasidone in human plasma by liquid chromatography-electrospray tandem mass spectrometry and its application to plasma level determination in schizophrenia patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Mar 01; 847(2):237-44. PMID: 17098485.
      View in: PubMed
    114. Marder SR. Initiatives to promote the discovery of drugs to improve cognitive function in severe mental illness. J Clin Psychiatry. 2006 Jul; 67(7):e03. PMID: 17107228.
      View in: PubMed
    115. Erhart SM, Marder SR, Carpenter WT. Treatment of schizophrenia negative symptoms: future prospects. Schizophr Bull. 2006 Apr; 32(2):234-7. PMID: 16492797; PMCID: PMC2632230.
    116. Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006 Apr; 32(2):214-9. PMID: 16481659; PMCID: PMC2632223.
    117. Charuvastra A, Marder S. Commentary on "TM and our models of informed consent" by Charles W. Lidz. Behav Sci Law. 2006; 24(4):547-52. PMID: 16883615.
      View in: PubMed
    118. Marder SR. The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia. Dialogues Clin Neurosci. 2006; 8(1):109-13. PMID: 16640121; PMCID: PMC3181758.
    119. Marder SR. Drug initiatives to improve cognitive function. J Clin Psychiatry. 2006; 67 Suppl 9:31-5; discussion 36-42. PMID: 16965187.
      View in: PubMed
    120. Marder SR. A review of agitation in mental illness: treatment guidelines and current therapies. J Clin Psychiatry. 2006; 67 Suppl 10:13-21. PMID: 16965191.
      View in: PubMed
    121. Erhart SM, Young AS, Marder SR, Mintz J. Clinical utility of magnetic resonance imaging radiographs for suspected organic syndromes in adult psychiatry. J Clin Psychiatry. 2005 Aug; 66(8):968-73. PMID: 16086610.
      View in: PubMed
    122. Glick ID, Marder SR. Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2005 May; 66(5):638-41. PMID: 15889952.
      View in: PubMed
    123. McGurk SR, Carter C, Goldman R, Green MF, Marder SR, Xie H, Schooler NR, Kane JM. The effects of clozapine and risperidone on spatial working memory in schizophrenia. Am J Psychiatry. 2005 May; 162(5):1013-6. PMID: 15863811.
      View in: PubMed
    124. Albers LJ, Ozdemir V, Marder SR, Raggi MA, Aravagiri M, Endrenyi L, Reist C. Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy. J Clin Psychopharmacol. 2005 Apr; 25(2):170-4. PMID: 15738749.
      View in: PubMed
    125. Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005 Mar; 162(3):441-9. PMID: 15741458.
      View in: PubMed
    126. Marder SR. Subjective experiences on antipsychotic medications: synthesis and conclusions. Acta Psychiatr Scand Suppl. 2005; (427):43-6. PMID: 15877721.
      View in: PubMed
    127. Quintana J, Wong T, Ortiz-Portillo E, Marder SR, Mazziotta JC. Anterior cingulate dysfunction during choice anticipation in schizophrenia. Psychiatry Res. 2004 Dec 15; 132(2):117-30. PMID: 15598546.
      View in: PubMed
    128. Marder SR, Fenton W. Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res. 2004 Dec 15; 72(1):5-9. PMID: 15531402.
      View in: PubMed
    129. Mohr PE, Cheng CM, Claxton K, Conley RR, Feldman JJ, Hargreaves WA, Lehman AF, Lenert LA, Mahmoud R, Marder SR, Neumann PJ. The heterogeneity of schizophrenia in disease states. Schizophr Res. 2004 Nov 01; 71(1):83-95. PMID: 15374576.
      View in: PubMed
    130. Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, Fenton WS, Frese F, Goldberg TE, Heaton RK, Keefe RS, Kern RS, Kraemer H, Stover E, Weinberger DR, Zalcman S, Marder SR. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry. 2004 Sep 01; 56(5):301-7. PMID: 15336511.
      View in: PubMed
    131. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004 Aug; 161(8):1334-49. PMID: 15285957.
      View in: PubMed
    132. Friedlander AH, Marder SR, Sung EC, Child JS. Panic disorder: psychopathology, medical management and dental implications. J Am Dent Assoc. 2004 Jun; 135(6):771-8; quiz 796-7. PMID: 15270162.
      View in: PubMed
    133. Miller A, Hall CS, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Ereshefsky L, Essock SM, Finnerty M, Marder SR, Miller DD, McEvoy JP, Rush AJ, Saeed SA, Schooler NR, Shon SP, Stroup S, Tarin-Godoy B. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry. 2004 Apr; 65(4):500-8. PMID: 15119912.
      View in: PubMed
    134. Bellack AS, Schooler NR, Marder SR, Kane JM, Brown CH, Yang Y. Do clozapine and risperidone affect social competence and problem solving? Am J Psychiatry. 2004 Feb; 161(2):364-7. PMID: 14754789.
      View in: PubMed
    135. Marder SR, Fenton W, Youens K. Schizophrenia, IX: Cognition in schizophrenia--the MATRICS initiative. Am J Psychiatry. 2004 Jan; 161(1):25. PMID: 14702244.
      View in: PubMed
    136. Friedlander AH, Friedlander IK, Marder SR. Posttraumatic stress disorder: psychopathology, medical management, and dental implications. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Jan; 97(1):5-11. PMID: 14716250.
      View in: PubMed
    137. Aravagiri M, Marder SR, Nuechterlein KH, Gitlin MJ. Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone. Ther Drug Monit. 2003 Dec; 25(6):657-64. PMID: 14639051.
      View in: PubMed
    138. Marder SR, Glynn SM, Wirshing WC, Wirshing DA, Ross D, Widmark C, Mintz J, Liberman RP, Blair KE. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am J Psychiatry. 2003 Aug; 160(8):1405-12. PMID: 12900301.
      View in: PubMed
    139. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003 Jul; 60(7):681-90. PMID: 12860772.
      View in: PubMed
    140. Quintana J, Wong T, Ortiz-Portillo E, Marder SR, Mazziotta JC. Right lateral fusiform gyrus dysfunction during facial information processing in schizophrenia. Biol Psychiatry. 2003 Jun 15; 53(12):1099-112. PMID: 12814861.
      View in: PubMed
    141. Friedlander AH, Marder SR, Pisegna JR, Yagiela JA. Alcohol abuse and dependence: psychopathology, medical management and dental implications. J Am Dent Assoc. 2003 Jun; 134(6):731-40. PMID: 12839410.
      View in: PubMed
    142. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003 Jun 01; 61(2-3):123-36. PMID: 12729864.
      View in: PubMed
    143. Quintana J, Wong T, Ortiz-Portillo E, Kovalik E, Davidson T, Marder SR, Mazziotta JC. Prefrontal-posterior parietal networks in schizophrenia: primary dysfunctions and secondary compensations. Biol Psychiatry. 2003 Jan 01; 53(1):12-24. PMID: 12513941.
      View in: PubMed
    144. Marder SR. Overview of partial compliance. J Clin Psychiatry. 2003; 64 Suppl 16:3-9. PMID: 14680412.
      View in: PubMed
    145. Marder SR, Conley R, Ereshefsky L, Kane JM, Turner MS. Clinical guidelines: Dosing and switching strategies for long-acting risperidone. J Clin Psychiatry. 2003; 64 Suppl 16:41-6. PMID: 14680418.
      View in: PubMed
    146. Tsuang JW, Eckman T, Marder S, Tucker D. Can risperidone reduce cocaine use in substance abusing schizophrenic patients? J Clin Psychopharmacol. 2002 Dec; 22(6):629-30. PMID: 12454567.
      View in: PubMed
    147. Tsuang J, Marder SR, Han A, Hsieh W. Olanzapine treatment for patients with schizophrenia and cocaine abuse. J Clin Psychiatry. 2002 Dec; 63(12):1180 -1. PMID: 12530415.
      View in: PubMed
    148. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry. 2002 Oct; 63(10):856-65. PMID: 12416594.
      View in: PubMed
    149. Merlo MC, Hofer H, Gekle W, Berger G, Ventura J, Panhuber I, Latour G, Marder SR. Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning. J Clin Psychiatry. 2002 Oct; 63(10):885-91. PMID: 12416598.
      View in: PubMed
    150. Friedlander AH, Friedlander IK, Marder SR. Bipolar I disorder: psychopathology, medical management and dental implications. J Am Dent Assoc. 2002 Sep; 133(9):1209-17. PMID: 12356252.
      View in: PubMed
    151. Wirshing DA, Pierre JM, Marder SR, Saunders CS, Wirshing WC. Sexual side effects of novel antipsychotic medications. Schizophr Res. 2002 Jul 01; 56(1-2):25-30. PMID: 12084416.
      View in: PubMed
    152. Green MF, Marder SR, Glynn SM, McGurk SR, Wirshing WC, Wirshing DA, Liberman RP, Mintz J. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry. 2002 Jun 15; 51(12):972-8. PMID: 12062881.
      View in: PubMed
    153. Glynn SM, Marder SR, Liberman RP, Blair K, Wirshing WC, Wirshing DA, Ross D, Mintz J. Supplementing clinic-based skills training with manual-based community support sessions: effects on social adjustment of patients with schizophrenia. Am J Psychiatry. 2002 May; 159(5):829-37. PMID: 11986138.
      View in: PubMed
    154. Umbricht DS, Wirshing WC, Wirshing DA, McMeniman M, Schooler NR, Marder SR, Kane JM. Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. J Clin Psychiatry. 2002 May; 63(5):420-4. PMID: 12019667.
      View in: PubMed
    155. Friedlander AH, Marder SR. The psychopathology, medical management and dental implications of schizophrenia. J Am Dent Assoc. 2002 May; 133(5):603-10; quiz 624-5. PMID: 12036166.
      View in: PubMed
    156. Kane JM, Davis JM, Schooler N, Marder S, Casey D, Brauzer B, Mintz J, Conley R. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry. 2002 Apr; 159(4):554-60. PMID: 11925292.
      View in: PubMed
    157. Marder SR, Essock SM, Miller AL, Buchanan RW, Davis JM, Kane JM, Lieberman J, Schooler NR. The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr Bull. 2002; 28(1):5-16. PMID: 12047022.
      View in: PubMed
    158. Marder SR. Can clinical practice guide a research agenda? Schizophr Bull. 2002; 28(1):127-9. PMID: 12047012.
      View in: PubMed
    159. Liberman RP, Glynn S, Blair KE, Ross D, Marder SR. In vivo amplified skills training: promoting generalization of independent living skills for clients with schizophrenia. Psychiatry. 2002; 65(2):137-55. PMID: 12108138.
      View in: PubMed
    160. Marder SR, Aravagiri M, Wirshing WC, Wirshing DA, Lebell M, Mintz J. Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate. Schizophr Res. 2002 Jan 01; 53(1-2):25-30. PMID: 11728835.
      View in: PubMed
    161. Aravagiri M, Marder SR. Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. Psychopharmacology (Berl). 2002 Feb; 159(4):424-31. PMID: 11823895.
      View in: PubMed
    162. Marder SR. Antipsychotic drugs and relapse prevention. Schizophr Res. 1999 Mar 01; 35 Suppl:S87-92. PMID: 10190229.
      View in: PubMed
    163. Marder SR, Wirshing WC, Mintz J, McKenzie J, Johnston K, Eckman TA, Lebell M, Zimmerman K, Liberman RP. Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia. Am J Psychiatry. 1996 Dec; 153(12):1585-92. PMID: 8942455.
      View in: PubMed